Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Simcere Announces Positive Data from Phase III Trial of Dual-Drug Oral Therapy for Stroke

publication date: Feb 22, 2024

Nanjing Simcere Pharma reported data from a Phase III trial of Sanbexin® sublingual tablets for acute ischemic stroke were published in an online Journal of American Medical Association•Neurology publication. Sanbexin is an edaravone-dexborneol combination that Simcere is developing with Nanjing’s Neurodawn Pharma, a CNS company. Simcere expects the Sanbexin® sublingual tablets will become a sequential therapy with Simcere's marketed Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection), allowing patients to complete their treatment at home. In June 2023, China’s NMPA accepted Simcere’s NDA filing for the combination therapy. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital